Q-omics provides the consensus-scored CCNB1IP1 profile across patient tissues and cancer cell-line models. CCNB1IP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCNB1IP1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CCNB1IP1 RNA expression shows 22,764 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where CCNB1IP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNB1IP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNB1IP1 survival associations across molecular data types. CCNB1IP1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNB1IP1 RNA expression–survival associations across cancer types. High CCNB1IP1 expression shows unfavorable associations in ACC, but favorable associations in KIRC, UVM, LGG, MESO and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCNB1IP1 RNA expression.
This table summarizes CCNB1IP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCNB1IP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNB1IP1 shows lower tumor expression in THCA, KIRC and BRCA and higher tumor expression in COAD, HNSC and READ. The COAD box plot shows higher CCNB1IP1 RNA expression in tumor versus normal tissue (log2 FC = +1.395, t-test p < 0.001).
This table shows molecular features associated with CCNB1IP1 in patient tissues and cancer cell lines. In patient samples, CCNB1IP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCNB1IP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
